Drug Information

Drug General Information
Drug ID
D0N6SO
Former ID
DCL000647
Drug Name
SYR-472
Drug Type
Small molecular drug
Indication Metabolic disorders [ICD9: 270-279; ICD10:E70-E89] Phase 3 [551987]
Company
Takeda
Formula
C22H26FN5O6
Canonical SMILES
CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N.C(C<br />C(=O)O)C(=O)O
InChI
1S/C18H20FN5O2.C4H6O4/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20;5-3(6)1-2-4(7)8/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3;1-2H2,(H,5,6)(H,7,8)/t15-;/m1./s1
InChIKey
OGCNTTUPLQTBJI-XFULWGLBSA-N
PubChem Compound ID
44183569
PubChem Substance ID
85178836, 89944234, 135268987, 135626897, 160692702, 163620870, 163686199, 186022496, 198986765, 227146427, 250163171, 251960901, 252161017, 252236923, 252448936, 252451805, 252481434
SuperDrug ATC ID
R03AC09
SuperDrug CAS ID
cas=018559596
Target and Pathway
Target(s) Dipeptidyl peptidase IV Target Info Inhibitor [532703], [551717]
KEGG Pathway Protein digestion and absorption
NetPath Pathway IL2 Signaling Pathway
TGF_beta_Receptor Signaling Pathway
References
Ref 551987Clinical pipeline report, company report or official report of Takeda.
Ref 532703SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.
Ref 551717Clinical pipeline report, company report or official report of Takeda (2009).